Risankizumab in the treatment of psoriasis – literature review
Risankizumab is a humanized, monoclonal antibody directed against subunit p19 of interleukin 23 (IL-23). In February 2019, risankizumab was approved for the treatment of moderate to severe psoriasis. The aim of the work is to collect up-to-date information on risankizumab and present its mechanism o...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Termedia Publishing House
2019-06-01
|
| Series: | Rheumatology |
| Subjects: | |
| Online Access: | https://www.termedia.pl/Risankizumab-in-the-treatment-of-psoriasis-literature-review,18,37110,1,1.html |